5 December 2012


(“Sareum” or “the Company”)

Issue of Equity

Sareum, the specialist cancer drug discovery business, announces the Company has drawn down £200,000 against its £4 million Standby Equity Distribution Agreement (“SEDA”) with YA Global Master SPV Ltd ('YA'), announced by the Company on 10 September 2012.

Under the terms of the SEDA, the Company has allotted, conditional on admission, 11,872,254 ordinary shares of 0.025 pence each in the capital of the Company (the “Drawdown Shares”) to YA at a price of 1.685 pence per share. This price is calculated by a formula under the terms of the SEDA and is based on the prevailing market price

Application will be made to the London Stock Exchange for the Drawdown Shares to be admitted to trading on AIM and it is expected that admission will become effective and trading will commence on 11 December 2012. The Drawdown Shares will rank, pari passu, with the existing ordinary shares of the Company.

Following the admission of the Drawdown Shares the Company will have a total of 1,492,175,847 ordinary shares in issue.

For further information:


Sareum Holdings plc

Tim Mitchell


01223 497 700

Merchant Securities Limited (Nomad)

Simon Clements


020 7628 2200

Hybridan LLP (Broker)

Claire Noyce, Deepak Reddy


020 7947 4350

The Communications Portfolio Limited (Media enquiries)

Philip Ranger / Caolan Mahon philip.ranger@communications-portfolio.co.uk


020 7536 2028 / 2029


Notes for editors:

About Sareum Holdings plc

Sareum is a drug discovery company, headquartered in Cambridge UK, that produces targeted small molecule therapeutics, focusing on cancer and auto-immune disease. Sareum aims to successfully deliver drug candidates for licensing to pharmaceutical and biotechnology companies at the pre-clinical or early clinical trials stage.

Sareum’s Chk1 kinase cancer research programme is a joint research collaboration with The Institute of Cancer Research and Cancer Research Technology Limited. The development candidate resulting from the collaboration increases the effectiveness of current cancer therapeutics in several in-vivo cancer models.

SKIL® (Sareum Kinase Inhibitor Library) is Sareum’s drug discovery technology platform that has so far produced the Company’s Aurora+FLT3, Aurora+ALK VEGFR-3, FLT3 & TYK2 kinase cancer and auto-immune disease research programmes. SKIL can also generate drug research programmes against other kinase targets.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange and trades under the symbol SAR.  For further information, please visit www.sareum.co.uk


About Yorkville Advisors

Yorkville Advisors is a US-based alternative investment manager.

For the last 10 years, Mark Angelo, President of Yorkville, has been specializing in providing flexible, innovative debt and equity investments and financing in publicly listed companies in a variety of sectors including mining, oil & gas, healthcare, real estate, manufacturing & shipping and technology.

Yorkville tailors its transactions on an investment by investment basis, which may include debt and equity investments, bridge financings, asset-backed or SEDA-backed notes, equity facilities and, straight equity participation.

Yorkville has offices in Jersey City, New Jersey; Palm Beach Gardens, Florida; Denver, Colorado and London.